Remuneration
Remuneration to board of directors
At the Annual General Meeting 2026, it was resolved that the remuneration to the Chair of the Board will be SEK 400,000 and SEK 175,000 to each of the members. Additionally, the Board’s audit committee Chair will receive a total of SEK 50,000 and each committee member SEK 25,000, and the Board’s remuneration committee Chair will receive SEK 50,000 and each committee member SEK 25,000.
| Name | Board function | Audit committee | Remuneration committee |
|---|---|---|---|
| Janne Backman | Chairperson | Chairperson | |
| James Gamgort | Member | ||
| Gunnar Olsson | Vice Chairperson | Member | |
| Rein Piir | Member | Member | |
| Veronica Wallin | Member | Chairperson |
Guidelines for remuneration to members of senior management
Remuneration policy resolved at the AGM on May 7, 2020 (and still valid after the AGM 2024)
In principal, the guidelines mean that member of senior management must be offered market compensation.
Read full policy (in Swedish only) >
Remuneration policy resolved at the AGM on April 25, 2019
In Swedish only.
Ersättningsfrågor behandlas av styrelsens ersättningsutskott och beslutas av styrelsen i sin helhet. Bolaget är kollektivanslutet och följer därmed gällande avtal och regler. VD och Bolagets ledningsgrupp utgör Bolagets ledande befattningshavare. Dessa ska erbjudas en marknadsmässig kompensation, som ska beakta den enskildes ansvarsområden och erfarenhet. Ersättningen ska bestå av fast lön och pension, med syfte att främja Bolagets långsiktiga värdeskapande. För VD gäller en ömsesidig uppsägningstid om 18 månader och för övriga ledande befattningshavare ska uppsägningstid enligt gällande kollektivavtal tillämpas. Inget avgångsvederlag utöver lön under uppsägningstiden förekommer.
Styrelsen har rätt att frångå ovanstående riktlinjer om styrelsen bedömer att det i ett enskilt fall finns särskilda skäl som motiverar det.
Remuneration policy resolved at the AGM on May 16, 2018
In Swedish only.
Ersättningsfrågor behandlas av styrelsens ersättningsutskott och beslutas av styrelsen i sin helhet. Bolaget är kollektivanslutet och följer därmed gällande avtal och regler. VD och Bolagets ledningsgrupp utgör Bolagets ledande befattningshavare. Dessa ska erbjudas en marknadsmässig kompensation, som ska beakta den enskildes ansvarsområden och erfarenhet. Ersättningen ska bestå av fast lön och pension, med syfte att främja Bolagets långsiktiga värdeskapande. För VD gäller en ömsesidig uppsägningstid om 18 månader och för övriga ledande befattningshavare ska uppsägningstid enligt gällande kollektivavtal tillämpas. Inget avgångsvederlag utöver lön under uppsägningstiden förekommer.
Styrelsen har rätt att frångå ovanstående riktlinjer om styrelsen bedömer att det i ett enskilt fall finns särskilda skäl som motiverar det.
Share- and share-price-related incentive schemes
Warrants programs
Directec Issue of Warrants to Fenja Capital II A/S.
The Annual General Meeting held on June 30, 2026 resolved on a directed issue of warrants to Fenja Capital in accordance with the loan agreement entered into between the Company and Fenja Capital in May, 2026, which became effective in July, 2026. Fenja Capital II A/S subscribed for 4,599,337 warrants of series 2026/2031 in the Company in July 2026. The warrants were issued free of charge. Each (1) warrant entitles the holder to subscribe for one (1) new Class A ordinary share in the Company at a subscription price of SEK 1.68 per share. The subscription price was determined through arm’s-length negotiations. Subscription for new Class A ordinary shares by exercise of
the warrants may take place from July, 2026 up to and including April 30, 2031. Upon full exercise of the warrants, the share capital may increase by a maximum of SEK 104,964.96.
Share-Based incentive Programme for the board of directors 2026/2029:1
The Annual General Meeting held on June 30, 2026 resolved to establish a warrant programme for members of the Board of Directors of IRLAB with a term of approximately three (3) years. Each warrant entitles the holder to subscribe for one (1) new Class A ordinary share during the period from September 1, 2029 up to and including September 29, 2029. The fair value of the warrants was calculated and determined by an independent third party using the Black-Scholes valuation model and amounted to SEK 0.1798 per warrant. The subscription price for shares subscribed for pursuant to the warrants was set at SEK 2.63 per Class A ordinary share. Three Board members subscribed for a total of 1,110,000 warrants of series 2026/2029:1 in July 2026, which, if fully exercised, would result in dilution of approximately 0.8%. Full exercise of the subscribed warrants would increase the share capital by a maximum of SEK 22,000.00.
Class B shares
IRLAB Therapeutics AB has had a share-price-related incentive scheme which consisted of Class B shares that could be converted to Class A shares. All holders of Class B shares executed their rights to convert the Class B shares to Class A shares during June 2019. In this conversion, 277,979 Class B shares were converted to an equal amount of Class A shares.
As a consequence of the scheme, the initial Class B owners still own Class B shares, but has no right to convert any further shares to Class A shares. The Class B shares has one vote per share (equal to Class A shares) but does not give the owner any economic rights (dividend, preference in a liquidation or any other economic right).